{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:51:04Z","timestamp":1791395464955,"version":"4.3.3"},"reference-count":54,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100007453","name":"Stiftung VERUM","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100021066","name":"Gates Ventures","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021066","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["alz-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Alz &amp;amp; Dem Diag Ass &amp;amp; Dis Mo"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Recent approvals of disease\u2010modifying therapies by the European Medicines Agency mark a historic shift in the treatment landscape of Alzheimer's disease (AD) within the European Union that will challenge national health\u2010care systems and require major adaptations and modernization. This Perspective article provides an overview of the major obstacles in Europe concerning successful implementation of amyloid\u2010targeting treatments and offers potential solutions to overcome them. Major hurdles include a lack of recognition regarding the critical importance of an early, biomarker\u2010based AD diagnosis; low acceptance of blood tests and digital cognitive screening tools; insufficient investment in magnetic resonance imaging capacities; and a fragmented infrastructure for clinical registries. We call on European clinicians, research institutions, and policy makers for a bold and coordinated action to urgently modernize diagnostic pathways and monitoring infrastructure to deliver novel AD treatments in a timely, safe, and equitable manner to all patients who may benefit.<\/jats:p>","DOI":"10.1002\/dad2.70367","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T03:19:26Z","timestamp":1782962366000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Obstacles and solutions for implementing amyloid\u2010targeting treatments in Europe"],"prefix":"10.1002","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-6104-8012","authenticated-orcid":false,"given":"Anna","family":"Hofmann","sequence":"first","affiliation":[{"name":"Department of Neurology and Knight Alzheimer Disease Research Center Washington University  St. Louis Missouri USA"},{"name":"German Network for Memory Clinics (DNG)  Aachen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Perneczky","sequence":"additional","affiliation":[{"name":"German Network for Memory Clinics (DNG)  Aachen Germany"},{"name":"Department of Psychiatry and Psychotherapy LMU Hospital  Munich Germany"},{"name":"German Center for Neurodegenerative Diseases (DZNE)  Munich Germany"},{"name":"Munich Cluster for Systems Neurology (SyNergy)  Munich Germany"},{"name":"Ageing Epidemiology (AGE) Research Unit, School of Public Health Imperial College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.r796"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101593"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2025.1232"},{"key":"e_1_2_14_5_1","unstructured":"Alzheimer Europe.Roche receives CE Mark for blood test to help rule out AD.https:\/\/www.alzheimer\u2010europe.org\/news\/roche\u2010receives\u2010ce\u2010mark\u2010blood\u2010test\u2010help\u2010rule\u2010out\u2010ad?language_content_entity=en"},{"key":"e_1_2_14_6_1","unstructured":"C2N Diagnostics\u2019 PrecivityAD2\u2122 Blood Test Receives MHRA Medical Device Certification in the United Kingdom.https:\/\/precivityad.com\/news\/k1e196pn490zw2wogr6sublpkxndp4"},{"key":"e_1_2_14_7_1","unstructured":"PrecivityAD\u2122 Blood Test's Reach Expands to Europe and California Following Initial Launch; Test Detects Alzheimer's Disease Pathology.https:\/\/www.businesswire.com\/news\/home\/20201208005906\/en\/PrecivityAD\u2010Blood\u2010Tests\u2010Reach\u2010Expands\u2010to\u2010Europe\u2010and\u2010California\u2010Following\u2010Initial\u2010Launch\u2010Test\u2010Detects\u2010Alzheimers\u2010Disease\u2010Pathology"},{"key":"e_1_2_14_8_1","unstructured":"https:\/\/www.leqembi.com\/\u2010\/media\/Files\/Leqembi\/Prescribing\u2010Information.pdf?hash=a88be7f8\u2010601d\u20104c21\u2010847d\u2010790c0186ef18"},{"key":"e_1_2_14_9_1","unstructured":"https:\/\/uspl.lilly.com\/kisunla\/kisunla.html#pi"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100150"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.2793"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.13239"},{"key":"e_1_2_14_13_1","unstructured":"Alzheimer's Network for Treatment and Diagnostics (ALZ\u2010NET).https:\/\/www.alz\u2010net.org\/"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(24)01883\u2010X"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13859"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2024.3770"},{"key":"e_1_2_14_17_1","unstructured":"A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER\u2010ALZ 3).https:\/\/clinicaltrials.gov\/study\/NCT05026866#study\u2010plan"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474\u20104422(25)00024\u20109"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00115\u2010023\u201001492\u20106"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000916"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010024\u201002869\u2010z"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474\u20104422(21)00361\u20106"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582\u2010024\u201000989\u20101"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195\u2010019\u20100532\u2010x"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14184"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582\u2010024\u201000977\u20105"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.13855"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70316"},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70535"},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.85"},{"key":"e_1_2_14_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100094"},{"key":"e_1_2_14_33_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2024.32"},{"key":"e_1_2_14_34_1","doi-asserted-by":"publisher","DOI":"10.1101\/2024.09.25.24314349"},{"key":"e_1_2_14_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12217"},{"key":"e_1_2_14_36_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD\u2010240728"},{"key":"e_1_2_14_37_1","doi-asserted-by":"publisher","DOI":"10.2196\/62706"},{"key":"e_1_2_14_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010025\u201003965\u20104"},{"key":"e_1_2_14_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13919"},{"key":"e_1_2_14_40_1","unstructured":"https:\/\/kneu.com\/?referrer=neu"},{"key":"e_1_2_14_41_1","unstructured":"10% of the EU's GDP went to healthcare in 2023.https:\/\/ec.europa.eu\/eurostat\/web\/products\u2010eurostat\u2010news\/w\/ddn\u201020251117\u20102#:~:text=%C2%A9%20Pressmaster\/Shutterstock.com per%20inhabitant%20increasing%20by%20155.6%25"},{"key":"e_1_2_14_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273\u2010022\u201001212\u2010z"},{"key":"e_1_2_14_43_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2023.94"},{"key":"e_1_2_14_44_1","doi-asserted-by":"publisher","DOI":"10.1177\/13558196231211141"},{"key":"e_1_2_14_45_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2024.24"},{"key":"e_1_2_14_46_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.592302"},{"key":"e_1_2_14_47_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12877\u2010015\u20100103\u20103"},{"key":"e_1_2_14_48_1","unstructured":"The first AI\u2010driven MRI solution for safer Alzheimer's treatment.https:\/\/www.icometrix.com\/post\/the\u2010first\u2010ai\u2010driven\u2010mri\u2010solution\u2010for\u2010safer\u2010alzheimer\u2010s\u2010treatment"},{"key":"e_1_2_14_49_1","unstructured":"https:\/\/en.perceiv.ai\/for-clinics"},{"key":"e_1_2_14_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12782"},{"key":"e_1_2_14_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100096"},{"key":"e_1_2_14_52_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.33786"},{"key":"e_1_2_14_53_1","doi-asserted-by":"publisher","DOI":"10.1017\/S135561772200042X"},{"key":"e_1_2_14_54_1","doi-asserted-by":"publisher","DOI":"10.1101\/2025.07.16.25331196"},{"key":"e_1_2_14_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.18902"}],"container-title":["Alzheimer's &amp; Dementia: Diagnosis, Assessment &amp; Disease Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dad2.70367","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/dad2.70367","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dad2.70367","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:57:11Z","timestamp":1791392231000},"score":1,"resource":{"primary":{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/10.1002\/dad2.70367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1002\/dad2.70367"],"URL":"https:\/\/doi.org\/10.1002\/dad2.70367","archive":["Portico"],"relation":{},"ISSN":["2352-8729","2352-8729"],"issn-type":[{"value":"2352-8729","type":"print"},{"value":"2352-8729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"2025-12-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70367"}}